Abstract
In the United States, there were an estimated 235,760 newly diagnosed lung cancer cases and 131,880 related deaths in 2021.1 Furthermore, incidence rates of lung adenocarcinoma are rising in certain subgroups that do not have screening guidelines.2,3 The incorporation of lung cancer-related biomarkers into risk stratification and prediction analyses could help improve or develop screening programs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
